GRI Bio Expands Share Offering Agreement

GRI Bio ( (GRI) ) has provided an update.

On May 23, 2025, GRI Bio, Inc. announced an increase in the maximum number of shares available under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, originally dated May 20, 2024. This move could potentially enhance the company’s financial flexibility and market presence, impacting its operations and stakeholder interests.

The most recent analyst rating on (GRI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.

Spark’s Take on GRI Stock

According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.

GRI Bio’s stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.

To see Spark’s full report on GRI stock, click here.

More about GRI Bio

GRI Bio, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative therapies.

Average Trading Volume: 479,382

Technical Sentiment Signal: Sell

Current Market Cap: $2.68M

See more data about GRI stock on TipRanks’ Stock Analysis page.